Gynecologic Cancers

Gynecologic oncology encompasses ovarian, cervical, and uterine (endometrial) cancers. Key advances include PARP inhibitor maintenance for BRCA-mutated ovarian cancer, mirvetuximab soravtansine for FRα-positive platinum-resistant ovarian disease, pembrolizumab-based regimens across all three histologies, tisotumab vedotin for cervical cancer, and dostarlimab/lenvatinib combinations for advanced endometrial cancer.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Gynecologic Cancers

• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Carboplatin (Paraplatin) — Alkylating Agent
• Paclitaxel (Taxol) — Taxane
• Bevacizumab (Avastin) — Monoclonal Antibody
• Olaparib (Lynparza) — PARP Inhibitor
• Niraparib (Zejula) — PARP Inhibitor
• Rucaparib (Rubraca) — PARP Inhibitor
• Mirvetuximab soravtansine-gynx (Elahere) — Antibody-Drug Conjugate
• Gemcitabine (Gemzar) — Antimetabolite
• Doxorubicin (Adriamycin) — Anthracycline
• Topotecan (Hycamtin) — Topoisomerase Inhibitor
• Docetaxel (Taxotere) — Taxane
• Tisotumab vedotin-tftv (Tivdak) — Antibody-Drug Conjugate
• Cisplatin (Platinol) — Alkylating Agent
• Dostarlimab (Jemperli) — Checkpoint Inhibitor
• Lenvatinib (Lenvima) — Tyrosine Kinase Inhibitor